PMID- 25685317
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210109
IS  - 2045-0869 (Print)
IS  - 2045-0877 (Electronic)
IS  - 2045-0869 (Linking)
VI  - 1
IP  - 2
DP  - 2014
TI  - Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for 
      basic and preclinical studies.
PG  - 153-161
AB  - Most patients (70-90%) with the multiple endocrine neoplasia type 1 (MEN1) 
      syndrome possess germline heterozygous mutations in MEN1 that predisposes to 
      tumors of multiple endocrine and nonendocrine tissues. Some endocrine tumors of 
      the kinds seen in MEN1 that occur sporadically in the general population also 
      possess somatic mutations in MEN1. Interestingly, the endocrine tumors of MEN1 
      are recapitulated in mouse models of Men1 loss that serve as a valuable resource 
      to understand the pathophysiology and molecular basis of tumorigenesis. Exploring 
      these endocrine tumors in mouse models using in vivo, ex vivo and in vitro 
      methods can help to follow the process of tumorigenesis, and can be useful for 
      preclinical testing of therapeutics and understanding their mechanisms of action.
FAU - Agarwal, Sunita K
AU  - Agarwal SK
AD  - National Institutes of Health, NIDDK, Metabolic Diseases Branch, Bldg 10, Room 
      8C-101, Bethesda, MD 20892, USA, Tel.: +1 301 402 7834.
LA  - eng
GR  - ZIA DK075035/ImNIH/Intramural NIH HHS/United States
GR  - ZIA DK075035-06/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Int J Endocr Oncol
JT  - International journal of endocrine oncology
JID - 101648548
PMC - PMC4327775
MID - NIHMS650043
OTO - NOTNLM
OT  - MEN1
OT  - cell cycle
OT  - epigenetic
OT  - menin
OT  - mouse models
OT  - tumor suppressor
OT  - tumorigenesis
COIS- Financial & competing interests disclosure This work was supported by the 
      Intramural Research Program of the NIH, National Institute of Diabetes and 
      Digestive and Kidney Diseases (Project number: 1ZIADK075035-03). The author has 
      no other relevant affiliations or financial involvement with any organization or 
      entity with a financial interest in or financial conflict with the subject matter 
      or materials discussed in the manuscript apart from those disclosed. No writing 
      assistance was utilized in the production of this manuscript.
EDAT- 2015/02/17 06:00
MHDA- 2015/02/17 06:01
PMCR- 2015/02/13
CRDT- 2015/02/17 06:00
PHST- 2015/02/17 06:00 [entrez]
PHST- 2015/02/17 06:00 [pubmed]
PHST- 2015/02/17 06:01 [medline]
PHST- 2015/02/13 00:00 [pmc-release]
AID - 10.2217/ije.14.16 [doi]
PST - ppublish
SO  - Int J Endocr Oncol. 2014;1(2):153-161. doi: 10.2217/ije.14.16.